Anavo Therapeutics, a global leader in unlocking the full therapeutic potential of phosphatase biology, announced the appointment of Shaun McNulty, DPhil, as Chief Scientific Officer (CSO) and the appointment of Anna Quattropani, PhD, as Senior Vice President of Chemistry and Non-Clinical Development. Dr. McNulty will oversee the implementation of Anavo’s strategy from discovery into clinical development and, together with Dr. Quattropani and Anavo’s management team, the continued design of Anavo’s first- and best-in-class phosphatase-targeting allosteric modulators.

“We are fortunate to welcome Anna and Shaun to the Anavo team at this stage of our company’s growth,” said Birgit Zech, PhD, Chief Executive Officer of Anavo Therapeutics. “Anna and Shaun’s industry knowledge and R&D experience will support Anavo’s progress in creating a proprietary portfolio of therapeutic programs and establishing a robust platform for phosphatase targeting across multiple indications.”

Shaun McNulty, DPhil, has more than 30 years of experience in the biopharma industry, with a focus on designing and developing therapeutics in oncology. He has served as Chief Scientific Officer at companies utilizing novel approaches in biology and chemistry, including Biosceptre, Inflection Biosciences and Awakn Life Sciences. He has led scientific R&D teams for companies such as Charles River, GSK, Pfizer and Syntaxin. Through his many roles, Dr. McNulty has supported the clinical development of Neurontin and Lyrica, obtained regulatory clearance for 5 drug candidates to enter the clinic, and identified and refined over 50 candidates for pre-clinical development. Dr. McNulty holds a DPhil in Biochemistry and Cell Biology and a BSc in Biochemistry from the University of York in the UK and performed post-doctoral research at the University of Cambridge on kinase-mediated neuronal cell signaling.

“Anna and Shaun’s industry knowledge and R&D experience will support Anavo’s progress in creating a proprietary portfolio of therapeutic programs and establishing a robust platform for phosphatase targeting across multiple indications.”

“Anavo’s IGNITE platform uniquely enables the rapid identification and development of therapeutics targeting phosphatases, initially thought to be undruggable targets,” said Dr. McNulty. “I am excited to join the Anavo team as we continue to accelerate our proprietary portfolio of programs targeting disease-relevant phosphatases toward clinical development and to build out our next-generation approach for phosphatase targeting.”

Anna Quattropani, PhD, joins Anavo with over 20 years of experience in medicinal chemistry and drug discovery. She has a successful track record designing multiple clinical candidates and driving them from discovery through clinical development. Dr. Quattropani has been working in diverse therapeutic areas, including neurodegenerative, inflammatory, autoimmune, and cardiovascular diseases, as well as women’s health. She has held senior leadership roles at Asceneuron and Draupnir and R&D roles at Serono and Merck KGaA. Dr. Quattropani is the inventor of several clinical molecules such as the O-GlcNAcase inhibitors ASN90 and ASN51 for neurodegenerative diseases and the oxytocin receptor antagonist Nolasiban. She obtained her PhD and MS in organic synthesis and organometallic chemistry at University of Geneva, Switzerland followed by postdoctoral training at the University of California, Irvine. Dr. Quattropani is the inventor of 49 patents and the author of 21 peer-reviewed publications.

“I am very proud to join Anavo’s outstanding team and help accelerate the discovery and development of phosphatase-targeting allosteric modulators to provide potential alternative therapeutic solutions for patients,” said Dr. Quattropani.

Anavo’s former CSO Gerhard Müller, PhD, joins the Scientific Advisory Board to continue contributing to the board’s drug discovery and development.

Singapore, September 25, 2023 – GIC announces the appointment of Mr Lawrence Wong, currently GIC Director, as Deputy Chairman. The appointment is effective 1 October 2023.

Mr Wong has been a GIC Director and Chairman of the Investment Strategies Committee (ISC) since 1 November 2018 and 7 July 2023 respectively. As Deputy Chairman, Mr Wong will assist the Chairman to lead the Board in overseeing GIC’s long-term asset allocation and portfolio performance.

Mr Wong is currently Singapore’s Deputy Prime Minister and Minister for Finance. He is the Chairman of the Monetary Authority of Singapore, and Chairman of Singapore Economic Development Board’s International Advisory Council. He is also a member of the Future Economy Council, the Research, Innovation and Enterprise Council and the National Research Foundation Board.

UltiMaker, the global leader in desktop 3D printing, announced it has appointed Michiel Alting von Geusau as Chief Executive Officer, replacing Nadav Goshen who is leaving to pursue a new endeavor. This change is effective as of September 4, 2023.

Ultimaker and MakerBot, two desktop 3D printing companies, merged last year to form UltiMaker. With a wide range of cutting-edge 3D printing solutions, including the popular S and Method series, UltiMaker is paving the way for innovation across industries. UltiMaker also offers the MakerBot sub-brand and the Sketch series, dedicated to advancing 3D printing education in the classroom.

“Nadav was integral in building the foundation of UltiMaker post merger, and we are excited to now have Michiel as our leader in this next phase of the company,” says Bart Markus, Chairman of the Supervisory Board. “Michiel is a seasoned and results-oriented leader with extensive experience in driving growth within technology companies.”

Michiel was previously the CEO and CFO of Docdata N.V., where he transformed the company and led its sale to Ingram Micro Commerce & Fulfillment. At Ingram Micro, Michiel was Global President for the business unit Commerce and Lifecycle Services. Throughout his career, Michiel has led the acquisition and seamless integration of multiple companies globally.

“I am honored to become the CEO of UltiMaker and grow the adoption of 3D printing across the globe,” says Michiel Alting von Geusau. “UltiMaker is a market leader with easy-to-use and accessible desktop 3D printing solutions for any application. I look forward to leading this innovative company with a bright future and industry leading products.”

Helene Thomas, Global Head of HR, is retiring. Since joining CVC in 2008, Helene has played an important role establishing our HR programmes that underpin CVC’s success as a leading global private markets manager. On behalf of the CVC Board, we thank Helene for her outstanding contribution and wish her the best for her retirement.

We are delighted to welcome Katharina Koenig to CVC as Chief People Officer and Partner.

Katharina will lead the HR strategy for our team of over 1,000 people across seven platforms and 29 offices, ensuring we continue to recruit, retain and develop the best talent in the industry. Katharina joins us from Goldman Sachs.

Patrik Andersson has been appointed Chairman of AAK’s Board of Directors until a new Chairman is
elected by the General Meeting. The appointment follows the deeply saddening and sudden passing
of AAK’s former Chairman of the Board, Georg Brunstam.

Patrik Andersson has been a valued member of AAK’s Board of Directors since 2019 and currently
serves as Chairman of Midsona AB, Sesol AB, and Cary Group AB, while also holding a board member
position at Ecolean AB. Patrik’s operational background includes six years as President and CEO of Loomis, as well as leadership roles at Unilever, Barilla, Rieber & Son, and Orkla.

For more information, please contact:

Carl Ahlgren
Head of IR & Corporate Communications
Mobile: +46 706 81 07 34 E-mail: carl.ahlgren@aak.com

The information was submitted for publication at 17:30 p.m. CET on September 11, 2023.

About AAK

Everything AAK does is about Making Better Happen™. We specialize in plant-based oils that are the value-adding ingredients in many of the products people love to consume. We make these products better tasting, healthier, and more sustainable. At the heart of AAK’s offer is Customer Co-Development, combining our desire to understand what better means for each customer, with the unique flexibility of our production assets, and a deep knowledge of many products and industries, including Chocolate & Confectionery, Bakery, Dairy, Plant-based Foods, Special Nutrition, Foodservice and Personal Care. Our 4,000 employees support our close collaboration with customers through 25 regional sales offices, 15 dedicated Customer Innovation Centers, and with the support of more than 20 production facilities. Listed on Nasdaq Stockholm and with our headquarters in Malmö, Sweden, AAK has been Making Better Happen for more than 150 years.

Providence Equity Partners (“Providence”), a premier private equity firm specializing in growth-oriented investments in media, communications, education and technology, today announced that Katie Lyndon has joined the firm as a Managing Director, Head of Investor Relations, based in the New York office. In this newly created role, Ms. Lyndon will lead Providence’s investor relations team, setting the firm’s fundraising strategy and overseeing all its investor relations activities globally.

Ms. Lyndon is a seasoned operating executive with over a decade of experience managing investor relations and business development for global asset managers. She joins Providence from Hillhouse Capital Management, where she served as Head of Capital Partnerships for North America and was a senior member of the firm’s Capital Strategy team. Previously, she managed investor relations and business development at middle-market private equity investment firms Harvest Partners and Waud Capital Partners.

“Katie’s proven investor relations leadership, strategic thinking and deep network of relationships across the global institutional investment community will help us further strengthen our LP relationships, build new partnerships, and enhance Providence’s position in the market as a leading investor in media, communications, education and technology,” said Davis Noell, Senior Managing Director and Co-Head of North America at Providence. “We are confident she will prove to be a valuable strategic asset as we continue to grow and develop the firm and the ways in which we approach the market. We’re excited to welcome her to this critical role as part of the broader Providence leadership team.”

I am thrilled to join the talented team at Providence,” said Ms. Lyndon. “Providence has extensive experience building and growing exceptional businesses and has long been a leader in sector-focused investing. I look forward to leveraging my experience to contribute to Providence’s continued success and partnership with investors.”

Ms. Lyndon holds an M.B.A. from The Wharton School of the University of Pennsylvania and an A.B. from Dartmouth College.

About Providence Equity Partners
Providence Equity Partners is a specialist private equity investment firm focused on growth oriented media, communications, education and technology companies across North America and Europe. Providence combines its partnership approach to investing with deep industry expertise to help management teams build exceptional businesses and generate attractive returns. Since its founding in 1989, Providence has invested over $35 billion across more than 170 private equity portfolio companies. With its headquarters in Providence, RI, the firm also has offices in New York, London, Boston and Atlanta. For more information, please visit www.provequity.com.

Contacts
Investors
InvestorRelations@provequity.com

Media
FGS Global
Andrew Cole/Kelsey Markovich
Prov@fgsglobal.com